DK3148532T3 - Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer - Google Patents
Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer Download PDFInfo
- Publication number
- DK3148532T3 DK3148532T3 DK15799889.9T DK15799889T DK3148532T3 DK 3148532 T3 DK3148532 T3 DK 3148532T3 DK 15799889 T DK15799889 T DK 15799889T DK 3148532 T3 DK3148532 T3 DK 3148532T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhibitor
- cancer
- treatment
- pharmaceutical combination
- thioredoxin reductase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462003575P | 2014-05-28 | 2014-05-28 | |
| PCT/IB2015/053963 WO2015181737A1 (en) | 2014-05-28 | 2015-05-27 | Pharmaceutical combination for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3148532T3 true DK3148532T3 (en) | 2021-04-26 |
Family
ID=54698208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15799889.9T DK3148532T3 (en) | 2014-05-28 | 2015-05-27 | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US10555931B2 (da) |
| EP (1) | EP3148532B1 (da) |
| DK (1) | DK3148532T3 (da) |
| ES (1) | ES2873959T3 (da) |
| WO (1) | WO2015181737A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111053768B (zh) | 2013-07-12 | 2023-12-12 | 皮拉马尔企业有限公司 | 用于治疗黑素瘤的药物组合 |
| US10555931B2 (en) * | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
| EP3181118B1 (en) * | 2015-12-14 | 2019-02-13 | Warszawski Uniwersytet Medyczny | Synergistic combination of txnr inhibitors and ascorbate for treatment of b cell malignancies |
| CA3103604C (en) * | 2016-03-28 | 2023-09-26 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| CN108290899B (zh) * | 2016-06-06 | 2020-09-18 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡咯并嘧啶化合物及其应用 |
| WO2018237344A1 (en) * | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | METHODS OF PATIENT SELECTION AND TREATMENT OF CANCERS OVEREXPRESSING TRXR OR PRDX |
| US11433074B2 (en) | 2017-06-22 | 2022-09-06 | Triact Therapeutics, Inc. | Methods of treating glioblastoma |
| CA3072087A1 (en) * | 2017-08-11 | 2019-02-14 | Board Of Regents, The University Of Texas System | Targeting kinases for the treatment of cancer metastasis |
| EP3687501A4 (en) | 2017-09-29 | 2021-06-23 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND THEIR USES |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2022018667A1 (en) * | 2020-07-24 | 2022-01-27 | Pfizer Inc. | Combination therapies using cdk2 and cdc25a inhibitors |
| EP4405395A4 (en) * | 2021-09-24 | 2025-08-06 | Dana Farber Cancer Inst Inc | PEPTIDYL-PROLYL CIS/TRANS ISOMERASE (PIN1) INHIBITORS, THEIR COMBINATIONS AND USES |
| US11541116B1 (en) | 2022-01-07 | 2023-01-03 | Kojin Therapeutics, Inc. | Methods and compositions for inducing ferroptosis in vivo |
| WO2024173833A1 (en) * | 2023-02-16 | 2024-08-22 | Mei Pharma, Inc. | Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284856A (en) | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| MXPA04005939A (es) | 2002-01-22 | 2005-01-25 | Warner Lambert Co | 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas. |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| BR122019010200B8 (pt) | 2003-05-22 | 2021-07-27 | Nerviano Medical Science S R L | compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| JP5498782B2 (ja) | 2006-06-21 | 2014-05-21 | ピラマル エンタープライジーズ リミテッド | 増殖性疾患治療用のエナンチオマー的に純粋なフラボン誘導体の調製方法 |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| EP2231147A2 (en) * | 2007-12-13 | 2010-09-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| US20110129456A1 (en) | 2008-05-05 | 2011-06-02 | Yaolin Wang | Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer |
| US20110104308A1 (en) * | 2008-05-09 | 2011-05-05 | Duke University | Treatment For Diseases Relying On Discovery That Thioredoxin Mediates Nitric Oxide |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| EP2429292B1 (en) * | 2009-05-08 | 2019-04-03 | Georgia State University Research Foundation | Compounds and compositions comprising cdk inhibitors and their use in the treatment of cancer |
| US8889744B2 (en) * | 2009-06-22 | 2014-11-18 | Jack L. Arbiser | Bis-trifluoromethyl honokiol analogs and their use in treating cancers |
| SG10201601909TA (en) * | 2011-03-11 | 2016-04-28 | Gilead Calistoga Llc | Combination Therapies For Hematologic Malignancies |
| TW201242597A (en) * | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| TW201300105A (zh) | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| US10555931B2 (en) * | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
-
2015
- 2015-05-27 US US15/313,543 patent/US10555931B2/en active Active
- 2015-05-27 DK DK15799889.9T patent/DK3148532T3/da active
- 2015-05-27 ES ES15799889T patent/ES2873959T3/es active Active
- 2015-05-27 EP EP15799889.9A patent/EP3148532B1/en active Active
- 2015-05-27 WO PCT/IB2015/053963 patent/WO2015181737A1/en not_active Ceased
-
2019
- 2019-12-23 US US16/725,601 patent/US11234963B2/en active Active
-
2021
- 2021-12-13 US US17/548,849 patent/US11925618B2/en active Active
-
2024
- 2024-02-02 US US18/431,035 patent/US12383529B2/en active Active
-
2025
- 2025-07-09 US US19/264,758 patent/US20250332145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170112809A1 (en) | 2017-04-27 |
| US11925618B2 (en) | 2024-03-12 |
| US20250332145A1 (en) | 2025-10-30 |
| EP3148532A4 (en) | 2018-01-03 |
| EP3148532B1 (en) | 2021-03-03 |
| WO2015181737A1 (en) | 2015-12-03 |
| US11234963B2 (en) | 2022-02-01 |
| US12383529B2 (en) | 2025-08-12 |
| ES2873959T3 (es) | 2021-11-04 |
| EP3148532A1 (en) | 2017-04-05 |
| US20240390325A1 (en) | 2024-11-28 |
| US20200138782A1 (en) | 2020-05-07 |
| US20220168273A1 (en) | 2022-06-02 |
| US10555931B2 (en) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3148532T3 (en) | Pharmaceutical Combination Comprising a CDK Inhibitor and a Thioredoxin Reductase Inhibitor for the Treatment of Cancer | |
| IL272948A (en) | ENPP1 inhibitors and their use for cancer treatment | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| AU2015342774B2 (en) | EZH2 inhibitors and uses thereof | |
| IL248455B (en) | igf-1r antibody-drug conjugate and its use for cancer treatment | |
| EP3154590A4 (en) | Combination therapy with glutaminase inhibitors | |
| EP3142707A4 (en) | Methods and compositions for prevention or treatment of a disease | |
| SG11201609770TA (en) | Combination therapies for the treatment of cancer | |
| EP3204360A4 (en) | Therapeutic compounds and uses thereof | |
| EP3116872A4 (en) | Combination therapy with glutaminase inhibitors | |
| IL258741B (en) | Combination of bcl-2 inhibitor and mek inhibitor for cancer treatment | |
| HUE053654T2 (hu) | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére | |
| EP3180000A4 (en) | Cancer diagnosis and therapy | |
| EP3157336A4 (en) | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer | |
| EP3226901A4 (en) | Combination therapy for treatment of cancer | |
| EP3226869A4 (en) | Kinase inhibitor prodrug for the treatment of cancer | |
| EP3152195A4 (en) | Mth1 inhibitors for treatment of cancer | |
| EP3185884A4 (en) | Combination therapy for treatment of cancer | |
| EP3185910A4 (en) | Methods and compositions for the treatment of cancer | |
| EP3182988A4 (en) | Disintegrin variants and pharmaceutical uses thereof | |
| SG11201605745VA (en) | Targeting clptm1l for treatment and prevention of cancer | |
| EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
| EP3107543A4 (en) | Vacuolin-1 as an inhibitor of autophagyand endosomal trafficking and the use thereof for inhibiting tumor progression | |
| EP3237002A4 (en) | Prevention of metastasis and recurrence after primary cancer treatment | |
| IL252493A0 (en) | Compounds for use in the prevention or treatment of cancer |